Age-related macular degeneration is a common cause of blindness, but adding some static noise to a patient’s vision can ...
Age-related macular degeneration (AMD) is the nation's leading cause of blindness in older adults, outpacing even glaucoma and cataracts, and nearly 1% of Americans age 40 and older have ...
Significantly lower AMD risk compared with other agents in cohort study ...
Diabetes: Personalized Care During Eye Checks Has No Benefit Adding personalized education and risk assessment to routine eye exams does not improve glycemic control among patients with diabetes, a ...
LONG BEACH, Calif. -- Concomitant treatment with drugs for geographic atrophy (GA) and neovascular macular degeneration (nAMD) appeared to have no major safety issues or significantly affect either ...
The first study to evaluate both eyes treated with a gene therapy targeting neovascular, or wet, age-related macular degeneration (AMD) has found the treatment as safe and effective in the second eye ...
The MarketWatch News Department was not involved in the creation of this content. Fannin Partners Awarded $300K Phase I SBIR Grant from the National Eye Institute to Advance First-in-Class ...
According to MingMed Biotechnology, 1 the QA102-CS201 trial enrolled 150 patients with intermediate atrophic AMD and randomly ...